Loading stock data…
TEM
$55.00-0.48 (-0.87%)
Market ClosedLast close May 1
Tempus AI, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Tempus AI, Inc. in the Healthcare sector is trading at $55.00. The stock is currently 47% below its 52-week high of $104.32, remaining 18.1% below its 200-day moving average. Technical signals show neutral RSI of 65 and bullish MACD crossover, explaining why TEM maintains its current current market pressure. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 65) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$55.00
Potential Upside
5%
Whystock Fair Value$57.75
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus15 analysts
Mean target$72.40+31.6%
Range$35.00 – $100.00
Fundamentals
Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop and its laboratory diagnostic capabilities, analytic...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$9.23B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-40.65%
Volume
Today's trading volume
4.49M
Recent News
Fulgent Genetics, Inc. (FLGT) Reports Q1 Loss, Beats Revenue Estimates
Fulgent Genetics (FLGT) delivered earnings and revenue surprises of -89.47% and +4.00%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Tempus AI (TEM) Partners with Keck Medicine of USC to Integrate AI Across Healthcare Network
Tempus AI Inc. (NASDAQ:TEM) is one of the best up and coming stocks with highest upside potential. On April 23, Tempus AI and the Keck School of Medicine of USC launched a multi-faceted collaboration aimed at integrating artificial intelligence and data-driven insights into Southern California’s healthcare landscape. This partnership will impact over 1.5 million annual […]
Is Tempus AI, Inc. (TEM) A Good Stock To Buy Now?
Is TEM a good stock to buy? We came across a bullish thesis on Tempus AI, Inc. on Joe Gannon’s Substack by Gannon Capital. In this article, we will summarize the bulls’ thesis on TEM. Tempus AI, Inc.’s share was trading at $56.78 as of April 20th. TEM’s trailing P/E was 39.30 according to Yahoo Finance. Tempus AI, Inc. operates as […]
Tempus AI vs. Illumina: Which Oncology Stock Is Worth Buying Now?
TEM and ILMN battle in precision oncology, but stronger stock gains, valuation and earnings outlook position ILMN as the more compelling pick now.
Assessing Tempus AI (TEM) Valuation After A Recent Share Price Bounce
Tempus AI (TEM) has been drawing attention after recent share price moves, with the stock showing a gain over the past month but a decline across the past 3 months and year to date. See our latest analysis for Tempus AI. The recent 10.61% 1 month share price return contrasts with a 16.38% 3 month share price decline and a 19.79% year to date share price loss. Recent momentum therefore appears more like a short term bounce than a sustained trend, even though the 1 year total shareholder return...